These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 19656678)

  • 1. Quinolines as a novel structural class of potent and selective PDE4 inhibitors. Optimisation for inhaled administration.
    Woodrow MD; Ballantine SP; Barker MD; Clarke BJ; Dawson J; Dean TW; Delves CJ; Evans B; Gough SL; Guntrip SB; Holman S; Holmes DS; Kranz M; Lindvaal MK; Lucas FS; Neu M; Ranshaw LE; Solanke YE; Somers DO; Ward P; Wiseman JO
    Bioorg Med Chem Lett; 2009 Sep; 19(17):5261-5. PubMed ID: 19656678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quinolines as a novel structural class of potent and selective PDE4 inhibitors: optimisation for oral administration.
    Lunniss CJ; Cooper AW; Eldred CD; Kranz M; Lindvall M; Lucas FS; Neu M; Preston AG; Ranshaw LE; Redgrave AJ; Ed Robinson J; Shipley TJ; Solanke YE; Somers DO; Wiseman JO
    Bioorg Med Chem Lett; 2009 Mar; 19(5):1380-5. PubMed ID: 19195882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors.
    Lacombe P; Chauret N; Claveau D; Day S; Deschênes D; Dubé D; Gallant M; Girard Y; Huang Z; Laliberté F; Lévesque JF; Liu S; Macdonald D; Mancini JA; Masson P; Nicholson DW; Nicoll-Griffith DA; Salem M; Styhler A; Young RN
    Bioorg Med Chem Lett; 2009 Sep; 19(17):5266-9. PubMed ID: 19640717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pyrazolopyridines as a novel structural class of potent and selective PDE4 inhibitors.
    Hamblin JN; Angell TD; Ballantine SP; Cook CM; Cooper AW; Dawson J; Delves CJ; Jones PS; Lindvall M; Lucas FS; Mitchell CJ; Neu MY; Ranshaw LE; Solanke YE; Somers DO; Wiseman JO
    Bioorg Med Chem Lett; 2008 Jul; 18(14):4237-41. PubMed ID: 18539455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pyrazolopyridines as potent PDE4B inhibitors: 5-heterocycle SAR.
    Mitchell CJ; Ballantine SP; Coe DM; Cook CM; Delves CJ; Dowle MD; Edlin CD; Hamblin JN; Holman S; Johnson MR; Jones PS; Keeling SE; Kranz M; Lindvall M; Lucas FS; Neu M; Solanke YE; Somers DO; Trivedi NA; Wiseman JO
    Bioorg Med Chem Lett; 2010 Oct; 20(19):5803-6. PubMed ID: 20732811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors.
    Gallant M; Chauret N; Claveau D; Day S; Deschênes D; Dubé D; Huang Z; Lacombe P; Laliberté F; Lévesque JF; Liu S; Macdonald D; Mancini J; Masson P; Mastracchio A; Nicholson D; Nicoll-Griffith DA; Perrier H; Salem M; Styhler A; Young RN; Girard Y
    Bioorg Med Chem Lett; 2008 Feb; 18(4):1407-12. PubMed ID: 18207397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The discovery and synthesis of highly potent subtype selective phosphodiesterase 4D inhibitors.
    Aspiotis R; Deschênes D; Dubé D; Girard Y; Huang Z; Laliberté F; Liu S; Papp R; Nicholson DW; Young RN
    Bioorg Med Chem Lett; 2010 Sep; 20(18):5502-5. PubMed ID: 20709547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable for administration by inhalation: in vitro, kinetic, and in vivo characterization.
    Tralau-Stewart CJ; Williamson RA; Nials AT; Gascoigne M; Dawson J; Hart GJ; Angell AD; Solanke YE; Lucas FS; Wiseman J; Ward P; Ranshaw LE; Knowles RG
    J Pharmacol Exp Ther; 2011 Apr; 337(1):145-54. PubMed ID: 21205923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacology of a potent and selective inhibitor of PDE4 for inhaled administration.
    Chapman RW; House A; Richard J; Prelusky D; Lamca J; Wang P; Lundell D; Wu P; Ting PC; Lee JF; Aslanian R; Phillips JE
    Eur J Pharmacol; 2010 Sep; 643(2-3):274-81. PubMed ID: 20621091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological evaluation of novel phthalazinone derivatives as topically active phosphodiesterase 4 inhibitors.
    Kagayama K; Morimoto T; Nagata S; Katoh F; Zhang X; Inoue N; Hashino A; Kageyama K; Shikaura J; Niwa T
    Bioorg Med Chem; 2009 Oct; 17(19):6959-70. PubMed ID: 19744860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor.
    Macdonald D; Mastracchio A; Perrier H; Dubé D; Gallant M; Lacombe P; Deschênes D; Roy B; Scheigetz J; Bateman K; Li C; Trimble LA; Day S; Chauret N; Nicoll-Griffith DA; Silva JM; Huang Z; Laliberté F; Liu S; Ethier D; Pon D; Muise E; Boulet L; Chan CC; Styhler A; Charleson S; Mancini J; Masson P; Claveau D; Nicholson D; Turner M; Young RN; Girard Y
    Bioorg Med Chem Lett; 2005 Dec; 15(23):5241-6. PubMed ID: 16168647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addressing species specific metabolism and solubility issues in a quinoline series of oral PDE4 inhibitors.
    Lunniss C; Eldred C; Aston N; Craven A; Gohil K; Judkins B; Keeling S; Ranshaw L; Robinson E; Shipley T; Trivedi N
    Bioorg Med Chem Lett; 2010 Jan; 20(1):137-40. PubMed ID: 19932963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of oxazole-based PDE4 inhibitors with picomolar potency.
    Kuang R; Shue HJ; Xiao L; Blythin DJ; Shih NY; Chen X; Gu D; Schwerdt J; Lin L; Ting PC; Cao J; Aslanian R; Piwinski JJ; Prelusky D; Wu P; Zhang J; Zhang X; Celly CS; Billah M; Wang P
    Bioorg Med Chem Lett; 2012 Apr; 22(7):2594-7. PubMed ID: 22401864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacology of a novel, orally active PDE4 inhibitor.
    Dastidar SG; Ray A; Shirumalla R; Rajagopal D; Chaudhary S; Nanda K; Sharma P; Seth MK; Balachandran S; Gupta N; Palle V
    Pharmacology; 2009; 83(5):275-86. PubMed ID: 19321962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Part 2: Structure-activity relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinase.
    Wurz RP; Pettus LH; Henkle B; Sherman L; Plant M; Miner K; McBride HJ; Wong LM; Saris CJ; Lee MR; Chmait S; Mohr C; Hsieh F; Tasker AS
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1680-4. PubMed ID: 20138761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of the fused bicyclic 4-amino-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors.
    Goto T; Shiina A; Yoshino T; Mizukami K; Hirahara K; Suzuki O; Sogawa Y; Takahashi T; Mikkaichi T; Nakao N; Takahashi M; Hasegawa M; Sasaki S
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3325-8. PubMed ID: 23602400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective inhibitors of tumor progression loci-2 (Tpl2) kinase with potent inhibition of TNF-alpha production in human whole blood.
    Wu J; Green N; Hotchandani R; Hu Y; Condon J; Huang A; Kaila N; Li HQ; Guler S; Li W; Tam SY; Wang Q; Pelker J; Marusic S; Hsu S; Perry Hall J; Telliez JB; Cui J; Lin LL
    Bioorg Med Chem Lett; 2009 Jul; 19(13):3485-8. PubMed ID: 19464884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of selective PDE4B inhibitors.
    Naganuma K; Omura A; Maekawara N; Saitoh M; Ohkawa N; Kubota T; Nagumo H; Kodama T; Takemura M; Ohtsuka Y; Nakamura J; Tsujita R; Kawasaki K; Yokoi H; Kawanishi M
    Bioorg Med Chem Lett; 2009 Jun; 19(12):3174-6. PubMed ID: 19447034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological evaluation of 5-carbamoyl-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors.
    Goto T; Shiina A; Yoshino T; Mizukami K; Hirahara K; Suzuki O; Sogawa Y; Takahashi T; Mikkaichi T; Nakao N; Takahashi M; Hasegawa M; Sasaki S
    Bioorg Med Chem; 2013 Nov; 21(22):7025-37. PubMed ID: 24094436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo characterization of GSK256066, a high-affinity inhaled phosphodiesterase 4 inhibitor.
    Nials AT; Tralau-Stewart CJ; Gascoigne MH; Ball DI; Ranshaw LE; Knowles RG
    J Pharmacol Exp Ther; 2011 Apr; 337(1):137-44. PubMed ID: 21205924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.